Latest Breaking News On - Biocon biologics mylan viatris - Page 1 : comparemela.com

There has been a flurry of activity relating to proposed EYLEA® (aflibercept) biosimilars in November, starting with a BPCIA litigation against Celltrion’s proposed biosimilar CT-P42.

United statesSamsung bioepisApril breyer menonBiocon biologicspetitionedregeneronBiocon biologics mylan viatrisMylan bioconBiocon biologics